vs
MARINEMAX INC（HZO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是MARINEMAX INC的1.5倍（$772.1M vs $527.4M），Revvity同比增速更快（5.9% vs -16.5%），过去两年Revvity的营收复合增速更高（9.0% vs -16.6%）
MarineMax Inc.是美国头部休闲船舶及游艇零售商，主营全新及二手休闲船艇销售，同时提供船舶维保、金融服务、保险、游艇租赁及航海主题活动等配套服务，覆盖北美市场的私人航海爱好者群体。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HZO vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$527.4M
营收增速更快
RVTY
高出22.3%
-16.5%
两年增速更快
RVTY
近两年复合增速
-16.6%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $527.4M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | 34.4% | — |
| 营业利润率 | 2.1% | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | -16.5% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.14 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HZORVTY
| Q1 26 | $527.4M | — | ||
| Q4 25 | $505.2M | $772.1M | ||
| Q3 25 | $552.2M | $698.9M | ||
| Q2 25 | $657.2M | $720.3M | ||
| Q1 25 | $631.5M | $664.8M | ||
| Q4 24 | $468.5M | $729.4M | ||
| Q3 24 | $563.1M | $684.0M | ||
| Q2 24 | $757.7M | $691.7M |
净利润HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | $-7.9M | $98.4M | ||
| Q3 25 | $-851.0K | $46.7M | ||
| Q2 25 | $-52.1M | $53.9M | ||
| Q1 25 | $3.3M | $42.2M | ||
| Q4 24 | $18.1M | $94.6M | ||
| Q3 24 | $4.0M | $94.4M | ||
| Q2 24 | $31.6M | $55.4M |
毛利率HZORVTY
| Q1 26 | 34.4% | — | ||
| Q4 25 | 31.8% | — | ||
| Q3 25 | 34.7% | 53.6% | ||
| Q2 25 | 30.4% | 54.5% | ||
| Q1 25 | 30.0% | 56.5% | ||
| Q4 24 | 36.2% | — | ||
| Q3 24 | 34.3% | 56.3% | ||
| Q2 24 | 32.0% | 55.7% |
营业利润率HZORVTY
| Q1 26 | 2.1% | — | ||
| Q4 25 | 1.0% | 14.5% | ||
| Q3 25 | 2.5% | 11.7% | ||
| Q2 25 | -6.3% | 12.6% | ||
| Q1 25 | 3.6% | 10.9% | ||
| Q4 24 | 8.3% | 16.3% | ||
| Q3 24 | 4.8% | 14.3% | ||
| Q2 24 | 8.1% | 12.4% |
净利率HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | -1.6% | 12.7% | ||
| Q3 25 | -0.2% | 6.7% | ||
| Q2 25 | -7.9% | 7.5% | ||
| Q1 25 | 0.5% | 6.4% | ||
| Q4 24 | 3.9% | 13.0% | ||
| Q3 24 | 0.7% | 13.8% | ||
| Q2 24 | 4.2% | 8.0% |
每股收益（稀释后）HZORVTY
| Q1 26 | $0.14 | — | ||
| Q4 25 | $-0.36 | $0.86 | ||
| Q3 25 | $0.08 | $0.40 | ||
| Q2 25 | $-2.42 | $0.46 | ||
| Q1 25 | $0.14 | $0.35 | ||
| Q4 24 | $0.77 | $0.77 | ||
| Q3 24 | $0.17 | $0.77 | ||
| Q2 24 | $1.37 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.1M | $919.9M |
| 总债务越低越好 | $338.7M | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HZORVTY
| Q1 26 | $189.1M | — | ||
| Q4 25 | $164.6M | $919.9M | ||
| Q3 25 | $170.4M | $931.4M | ||
| Q2 25 | $151.0M | $991.8M | ||
| Q1 25 | $203.5M | $1.1B | ||
| Q4 24 | $145.0M | $1.2B | ||
| Q3 24 | $224.3M | $1.2B | ||
| Q2 24 | $242.4M | $2.0B |
总债务HZORVTY
| Q1 26 | $338.7M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $393.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $391.2M | — | ||
| Q2 24 | — | — |
股东权益HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | $932.8M | $7.3B | ||
| Q3 25 | $937.2M | $7.4B | ||
| Q2 25 | $940.5M | $7.6B | ||
| Q1 25 | $993.4M | $7.6B | ||
| Q4 24 | $993.5M | $7.7B | ||
| Q3 24 | $975.8M | $7.9B | ||
| Q2 24 | $967.6M | $7.9B |
总资产HZORVTY
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $2.5B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.7B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.6B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B |
负债/权益比HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | $16.9M | $182.0M | ||
| Q3 25 | $61.5M | $138.5M | ||
| Q2 25 | $84.9M | $134.3M | ||
| Q1 25 | $72.5M | $128.2M | ||
| Q4 24 | $-146.1M | $174.2M | ||
| Q3 24 | $-782.0K | $147.9M | ||
| Q2 24 | $86.3M | $158.6M |
自由现金流HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | $8.3M | $161.8M | ||
| Q3 25 | $48.0M | $120.0M | ||
| Q2 25 | $68.5M | $115.5M | ||
| Q1 25 | $59.8M | $112.2M | ||
| Q4 24 | $-164.4M | $149.8M | ||
| Q3 24 | $-17.5M | $125.6M | ||
| Q2 24 | $71.1M | $136.6M |
自由现金流率HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.7% | 21.0% | ||
| Q3 25 | 8.7% | 17.2% | ||
| Q2 25 | 10.4% | 16.0% | ||
| Q1 25 | 9.5% | 16.9% | ||
| Q4 24 | -35.1% | 20.5% | ||
| Q3 24 | -3.1% | 18.4% | ||
| Q2 24 | 9.4% | 19.7% |
资本支出强度HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.7% | 2.6% | ||
| Q3 25 | 2.4% | 2.6% | ||
| Q2 25 | 2.5% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 3.9% | 3.4% | ||
| Q3 24 | 3.0% | 3.3% | ||
| Q2 24 | 2.0% | 3.2% |
现金转化率HZORVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 21.97× | 3.03× | ||
| Q4 24 | -8.09× | 1.84× | ||
| Q3 24 | -0.20× | 1.57× | ||
| Q2 24 | 2.74× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HZO
| Retail Operations | $525.3M | 100% |
| Product Manufacturing | $23.7M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
